Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

53.03 -0.06 (-0.11%)
Streaming Delayed Price Updated: 2:02 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
1 Mid-Cap Stock to Research Further and 2 That Underwhelm
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from... 
Via StockStory
10x Genomics, BioMarin Pharmaceutical, AMN Healthcare Services, Illumina, and Moderna Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump. 
Via StockStory
Topics Economy Government World Trade
Is BioMarin Pharmaceutical Inc Gaining or Losing Market Support?
 
Via Benzinga
6 Analysts Assess BioMarin Pharmaceutical: What You Need To Know
 
Via Benzinga
Earnings Scheduled For August 4, 2025
 
Via Benzinga
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Presents a Compelling Value Investment Case
BioMarin is a strong value stock with a low P/E ratio, robust financial health, and solid profitability, offering a compelling safety margin for investors. 
Via Chartmill
Peering Into BioMarin Pharmaceutical's Recent Short Interest
 
Via Benzinga
2 Profitable Stocks on Our Watchlist and 1 We Turn Down
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. 
Via StockStory
Reflecting On Therapeutics Stocks’ Q2 Earnings: BioMarin Pharmaceutical (NASDAQ:BMRN)
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how BioMarin Pharmaceutical... 
Via StockStory
Topics Artificial Intelligence
PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment
BioMarin's Palynziq significantly lowered blood phenylalanine in teens with PKU, with nearly half reaching target levels in the Phase 3 study. 
Via Benzinga
Why BioMarin Pharmaceutical (BMRN) Stock Is Down Today
Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) fell 2.8% in the morning session after HC Wainwright & Co. initiated coverage on the stock with a Neutral rating and a $60 price target. 
Via StockStory
Topics Artificial Intelligence Economy
Forecasting The Future: 5 Analyst Projections For BioMarin Pharmaceutical
 
Via Benzinga
This Duolingo Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
 
Via Benzinga
2 Growth Stocks to Stash and 1 We Ignore
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s... 
Via StockStory
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): A Value Investing Case Study in Undervaluation
BioMarin Pharmaceutical (BMRN) is a top value investing pick, trading at a discount with strong financial health, high profitability, and solid growth potential. 
Via Chartmill
2 Safe-and-Steady Stocks to Keep an Eye On and 1 Facing Challenges
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. 
Via StockStory
What's Driving the Market Sentiment Around BioMarin Pharmaceutical?
 
Via Benzinga
3 of Wall Street’s Favorite Stocks to Consider Right Now
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
2 Reasons to Watch BMRN and 1 to Stay Cautious
Over the past six months, BioMarin Pharmaceutical’s stock price fell to $57. Shareholders have lost 17.1% of their capital, which is disappointing considering the S&P 500 has climbed by 4.7%. This may... 
Via StockStory
Topics Stocks
Predicting the Next Rule Breaker Buyout
Having a stock you own get acquired at a premium feels good at first, but what about the long-term gains that will be left behind when your chips are off the table? 
Via The Motley Fool
Topics Artificial Intelligence
Elliott Management Bets Against S&P 500, Nasdaq 100, Nvidia Stock In Second Quarter
Elliott Management places new bets against the market in the second quarter, while taking a new long position in Hewlett Packard Enterprise. 
Via Benzinga
Topics Stocks
Azenta, LifeStance Health Group, BioMarin Pharmaceutical, AMN Healthcare Services, and ANI Pharmaceuticals Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer... 
Via StockStory
Topics Earnings Economy
BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN): A Prime Value Investment with Strong Fundamentals and Growth Potential
Value investing highlights undervalued stocks like BioMarin Pharmaceutical, with strong financials, earnings, and growth potential, offering a margin of safety. 
Via Chartmill
BMRN Q2 Deep Dive: Pipeline Advances and Strategic Expansion Drive Upbeat Results
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 15.9% year on year to $825.4 million. The company’s full-year... 
Via StockStory
Is BioMarin Pharmaceutical Gaining or Losing Market Support?
 
Via Benzinga
BioMarin Discontinues Preclinical Drug Candidate, Advances BMN 333 Toward 2030
BioMarin beats Q2 expectations on strong enzyme therapy sales and raises full-year earnings and revenue guidance amid continued Voxzogo growth. 
Via Benzinga
BioMarin (BMRN) Q2 Revenue Jumps 16%
Via The Motley Fool
Topics Economy
BioMarin (BMRN) Q2 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
BioMarin Pharmaceutical (NASDAQ:BMRN) Delivers Strong Q2 Numbers, Stock Soars
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 15.9% year on year to $825.4 million. The company’s full-year... 
Via StockStory
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Exceeds Q2 2025 Earnings Expectations, Shares Climb After Hours
BioMarin Pharmaceutical beats Q2 2025 estimates with $825.4M revenue, EPS of $1.44, and raises full-year guidance. Stock surges 4.6% post-earnings. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.